Vassiliki Poulaki

Summary

Publications

  1. ncbi BMS-275291. Bristol-Myers Squibb
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114, USA
    Curr Opin Investig Drugs 3:500-4. 2002
  2. ncbi The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro
    Vassiliki Poulaki
    Angiogenesis Laser Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 48:4706-19. 2007
  3. ncbi Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Invest Ophthalmol Vis Sci 46:358-66. 2005
  4. ncbi Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability
    Vassiliki Poulaki
    Retina Research and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 325 Cambridge Street, Boston, MA 02114, USA
    Am J Pathol 161:2229-40. 2002
  5. ncbi Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Pathol 161:643-54. 2002
  6. ncbi Microdissection, microarrays and proteomics: a new approach to the study of eye diseases
    Vassiliki Poulaki
    Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 325 Cambridge Street, Boston, MA 02115, USA
    Graefes Arch Clin Exp Ophthalmol 241:527-8. 2003
  7. ncbi The role of Fas and FasL as mediators of anticancer chemotherapy
    V Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Drug Resist Updat 4:233-42. 2001
  8. ncbi Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications
    Vassiliki Poulaki
    Department of Ophthalmology, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
    Invest Ophthalmol Vis Sci 50:4072-9. 2009
  9. ncbi Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    J Clin Endocrinol Metab 91:4013-21. 2006
  10. ncbi Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 92:4845-52. 2007

Detail Information

Publications43

  1. ncbi BMS-275291. Bristol-Myers Squibb
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114, USA
    Curr Opin Investig Drugs 3:500-4. 2002
    ..In January 2002, Morgan Stanley Dean Witter expressed the view that release of positive phase II/III trials data would surprise stock markets...
  2. ncbi The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro
    Vassiliki Poulaki
    Angiogenesis Laser Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 48:4706-19. 2007
    ..NF-kappaB, which is constitutively active in human retinoblastoma cells and promotes their survival, represents a therapeutic target for patients with this malignancy...
  3. ncbi Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Invest Ophthalmol Vis Sci 46:358-66. 2005
    ..TRAIL signals through its receptors DR4 and DR5, which can activate caspase-8 as well. This study was undertaken to investigate the functional status of the FasL and TRAIL apoptotic pathways in retinoblastoma (Rb) cells...
  4. ncbi Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability
    Vassiliki Poulaki
    Retina Research and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 325 Cambridge Street, Boston, MA 02114, USA
    Am J Pathol 161:2229-40. 2002
    ..Therapeutic strategies targeting NF-kappaB could be beneficial in the clinical management of Rb, either alone or in combination with conventional chemotherapy...
  5. ncbi Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Pathol 161:643-54. 2002
    ..T helper-1 cytokines and compounds that selectively abrogate the IGF-1 signaling pathway may be helpful adjunct agents in Apo2L/TRAIL-based anti-cancer therapeutic regimens...
  6. ncbi Microdissection, microarrays and proteomics: a new approach to the study of eye diseases
    Vassiliki Poulaki
    Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 325 Cambridge Street, Boston, MA 02115, USA
    Graefes Arch Clin Exp Ophthalmol 241:527-8. 2003
  7. ncbi The role of Fas and FasL as mediators of anticancer chemotherapy
    V Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Drug Resist Updat 4:233-42. 2001
    ..The combined use of MMP inhibitors with conventional, cytotoxic chemotherapy may hold therapeutic benefit...
  8. ncbi Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications
    Vassiliki Poulaki
    Department of Ophthalmology, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
    Invest Ophthalmol Vis Sci 50:4072-9. 2009
    ..Vorinostat has demonstrated significant anticancer activity against hematologic and solid tumors at doses well tolerated by patients and has been approved for the treatment of patients with cutaneous T-cell lymphoma...
  9. ncbi Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    J Clin Endocrinol Metab 91:4013-21. 2006
    ..NF-kappaB has been implicated in the pathophysiology of the most aggressive forms of thyroid carcinoma, i.e. medullary and anaplastic...
  10. ncbi Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 92:4845-52. 2007
    ..The Bcl-2 family of proteins regulates apoptosis in various models and may represent a promising therapeutic target in human malignancies...
  11. ncbi Suppression of diabetic retinopathy with angiopoietin-1
    Antonia M Joussen
    Laboratory for Surgical Research, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Pathol 160:1683-93. 2002
    ..Taken together, these data document new vascular and anti-inflammatory bioactivities for angiopoietin-1 and identify it as the first naturally occurring protein that directly protects the retinal vasculature in diabetes...
  12. ncbi Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy
    Eirini Iliaki
    Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 50:4898-904. 2009
    ..The authors have now studied the role of integrin alpha 4/CD49d in the pathogenesis of diabetic retinopathy...
  13. ncbi Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis
    Vassiliki Poulaki
    Angiogenesis Laser Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles St, Boston, MA 02114, USA
    FASEB J 21:2113-23. 2007
    ..17-AAG has demonstrated a favorable safety profile in clinical trials in cancer patients and represents a promising therapeutic agent for the treatment of inflammatory eye diseases...
  14. ncbi The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2377-80. 2003
    ..These studies, therefore, provide the framework for clinical use of this agent in combination with conventional chemotherapy...
  15. ncbi Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:5673-83. 2002
    ..Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1...
  16. ncbi Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas
    Vassiliki Poulaki
    Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 88:5392-8. 2003
    ....
  17. ncbi Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy
    Vassiliki Poulaki
    Retina Research Institute, Massachusetts Eye and Ear Infirmary, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Am J Pathol 165:457-69. 2004
    ..Taken together, these in vitro and in vivo signaling studies thus identify potential targets for pharmacological intervention to preserve vision in patients with diabetes...
  18. ncbi Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  19. ncbi Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF
    Vassiliki Poulaki
    Laboratory of Surgical Research, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 109:805-15. 2002
    ..To our knowledge, these data are the first to identify a specific mechanism for the transient worsening of diabetic retinopathy, specifically blood-retinal barrier breakdown, that follows the institution of intensive insulin therapy...
  20. ncbi Novel histone deacetylase inhibitors in the treatment of thyroid cancer
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 11:3958-65. 2005
    ..g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available...
  21. ncbi Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
    ....
  22. ncbi Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
    ....
  23. ncbi Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 91:3662-6. 2006
    ..EGFR inhibitors have produced objective responses in patients with non-small-cell lung carcinomas harboring activating EGFR TK domain somatic mutations...
  24. ncbi Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    Mol Cancer Ther 6:1070-8. 2007
    ..Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer...
  25. ncbi Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4079-86. 2002
    ..These studies provide the framework for targeting NF-kappaB activity in novel biologically based therapies for MM...
  26. ncbi VEGF-dependent conjunctivalization of the corneal surface
    Antonia M Joussen
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA
    Invest Ophthalmol Vis Sci 44:117-23. 2003
    ..Both processes are probably mediated, in part, through the Flt-1 receptor. Taken together, these data indicate that an anti-VEGF therapeutic approach may limit the visual loss associated with conjunctivalization of the corneal surface...
  27. ncbi Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4525-30. 2002
    ..These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM...
  28. ncbi Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Room M555, Mayer Building, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 12:3705-12. 2006
    ..The death receptor Fas is present in thyroid carcinomas, yet fails to trigger apoptosis. Interestingly, Fas has been reported to be actually overexpressed in papillary thyroid carcinomas, suggesting that it may confer a survival advantage...
  29. ncbi Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes
    Antonia M Joussen
    Retina Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    FASEB J 17:76-8. 2003
    ..These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy...
  30. ncbi Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 101:4055-62. 2003
    ....
  31. ncbi Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo
    Antonia M Joussen
    Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA
    Am J Pathol 160:501-9. 2002
    ..The inhibition of VEGF bioactivity may prove useful in the treatment of the early diabetic retinopathy...
  32. ncbi Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
    ..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM...
  33. ncbi Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer Bldg, Boston, MA 02115, USA
    Blood 99:2162-71. 2002
    ..Our data set a framework for the clinical use of approaches that sensitize MM cells to TRAIL by agents that inhibit FLIP and cIAP-2 expression or augment caspase-8 activity...
  34. ncbi Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression
    Vassiliki Poulaki
    Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, and the Dana Faber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Am J Pathol 164:1293-302. 2004
    ..We conclude that activin A stimulates inflammatory corneal angiogenesis by increasing VEGF levels through a p38 and p42/44 MAPK-dependent mechanism...
  35. ncbi Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression
    Antonia M Joussen
    Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    FASEB J 16:438-40. 2002
    ..Taken together, these data identify COX-2 and TNF-alpha as operative in the early signature pathologies of diabetic retinopathy, a newly recognized inflammatory disease...
  36. ncbi Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity
    N Mitsiades
    Massachusetts General Hospital, and Department of Pathology, Harvard Medical School, Boston 02129, USA
    Cancer Res 61:577-81. 2001
    ..Our observations provide evidence that one mechanism whereby MMP-7 may promote tumor survival and resistance to doxorubicin is by cleaving FasL and reducing its effectiveness in triggering Fas-mediated apoptosis...
  37. ncbi The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer
    C S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Endocrinol 178:205-16. 2003
    ..Pharmacological modulation of apoptosis induced by FasL and TRAIL/Apo2L holds promise of therapeutic applications in human malignancies...
  38. ncbi Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand
    N Mitsiades
    Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA
    Cancer Res 60:4122-9. 2000
    ....
  39. ncbi Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases
    N Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Mayer Building, Room M557, 44 Binney Street, Boston, MA 02115, USA
    Trends Endocrinol Metab 12:384-90. 2001
    ..FasL is expressed by neoplastic thyrocytes and induces apoptosis of infiltrating lymphocytes. TRAIL/Apo2L kills thyroid carcinoma cells but spares normal thyrocytes, thus providing a potential therapy for thyroid cancer...
  40. ncbi Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines
    Constantine S Mitsiades
    J Clin Endocrinol Metab 88:5043-4; author reply 5044. 2003
  41. ncbi Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo
    Kan Koizumi
    Department of Vitreoretinal Surgery, Center for Ophthalmology, and Center for Molecular Medicine, University of Cologne, Cologne, Germany
    Invest Ophthalmol Vis Sci 44:2184-91. 2003
    ..These results suggest the involvement of TNF-alpha in inflammatory uveitis and its potential use as a therapeutic agent in the reduction of ocular inflammation...
  42. ncbi Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization
    Irina Semkova
    Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Cologne, Germany
    FASEB J 20:1689-91. 2006
    ..The specific overexpression of FasL in RPE layer reduced CNV formation in our laser model. Our results strongly point to the FasL-Fas pathway as a potential therapeutic target in controlling pathological choroidal neovascularization...
  43. ncbi Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity
    Norbert Kociok
    Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Graefes Arch Clin Exp Ophthalmol 245:258-66. 2007
    ..Here we use a mouse model of oxygen-induced retinopathy to investigate the effect of 17-AAG on retinal neovascularization and vascular recovery...